Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Equity (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Return on Equity for 6 consecutive years, with 0.72% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 33.0% year-over-year to 0.72%, compared with a TTM value of 0.72% through Sep 2025, down 33.0%, and an annual FY2024 reading of 0.34%, up 14.0% over the prior year.
  • Return on Equity was 0.72% for Q3 2025 at Ovid Therapeutics, down from 0.66% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.87% in Q1 2021 and bottomed at 0.72% in Q3 2025.
  • Average Return on Equity over 5 years is 0.23%, with a median of 0.4% recorded in 2022.
  • The sharpest move saw Return on Equity surged 216bps in 2021, then crashed -127bps in 2022.
  • Year by year, Return on Equity stood at 0.65% in 2021, then crashed by -161bps to 0.39% in 2022, then plummeted by -40bps to 0.55% in 2023, then surged by 34bps to 0.37% in 2024, then crashed by -98bps to 0.72% in 2025.
  • Business Quant data shows Return on Equity for OVID at 0.72% in Q3 2025, 0.66% in Q2 2025, and 0.39% in Q1 2025.